PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to “trick” the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).
PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti?PD-1/PD-L1 therapies.
PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.
PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.
This report contains market size and forecasts of PD-L1 and PIK3CA Testing in Global, including the following market information:
Global PD-L1 and PIK3CA Testing Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global top five companies in 2021 (%)
The global PD-L1 and PIK3CA Testing market was valued at 536.9 million in 2021 and is projected to reach US$ 1892 million by 2028, at a CAGR of 19.7% during the forecast period.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
PD-L1 Testing Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of PD-L1 and PIK3CA Testing include Agilent Technologies, Roche, QIAGEN, EntroGen, Amoy Diagnostics and ACCB Biotech, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
We surveyed the PD-L1 and PIK3CA Testing companies, and industry experts on this industry, involving the revenue, demand, product type, recent developments and plans, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global PD-L1 and PIK3CA Testing Market, by Type, 2017-2022, 2023-2028 ($ millions)
Global PD-L1 and PIK3CA Testing Market Segment Percentages, by Type, 2021 (%)
Global PD-L1 and PIK3CA Testing Market, by Application, 2017-2022, 2023-2028 ($ millions)
Global PD-L1 and PIK3CA Testing Market Segment Percentages, by Application, 2021 (%)
Global PD-L1 and PIK3CA Testing Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions)
Global PD-L1 and PIK3CA Testing Market Segment Percentages, By Region and Country, 2021 (%)
Rest of Europe
Rest of Asia
Rest of South America
Middle East & Africa
Rest of Middle East & Africa
The report also provides analysis of leading market participants including:
Key companies PD-L1 and PIK3CA Testing revenues in global market, 2017-2022 (estimated), ($ millions)
Key companies PD-L1 and PIK3CA Testing revenues share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include: